These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 7388826)

  • 1. Effect of cyclophosphamide on mice bearing methylcholanthrene-induced fibrosarcomas.
    Yu S; Lannin DR; Tsui-Collins AL; McKhann CF
    Cancer Res; 1980 Aug; 40(8 Pt 1):2756-61. PubMed ID: 7388826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose cyclophosphamide inhibition of transplantable fibrosarcoma growth by augmentation of the host immune response.
    Ray PK; Raychaudhuri S
    J Natl Cancer Inst; 1981 Dec; 67(6):1341-5. PubMed ID: 6947115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB; Hengst JC; Dray S
    Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific immune responsiveness of the tumor-bearing host.
    Burk MW; Yu S; McKhann CF
    Isr J Med Sci; 1976; 12(4-5):360-8. PubMed ID: 939694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW; Mokyr MB
    Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of allogeneic tumor transplants: induced rejection of advanced tumors by immune alteration of recipients.
    Russell PS; Chase CM; Burton RC
    J Immunol; 1983 Feb; 130(2):951-7. PubMed ID: 6336775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Corynebacterium granulosum on weight and histology of lymphoid organs, response to mitogens, skin allografts, and a syngeneic fibrosarcoma in mice.
    Milas L; Basic I; Kogelnik HD; Withers HR
    Cancer Res; 1975 Sep; 35(9):2365-74. PubMed ID: 807323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Nocardia rubra cell wall skeleton on T-cell-mediated cytotoxicity in mice bearing syngeneic sarcoma.
    Kawase I; Uemiya M; Yoshimoto T; Ogura T; Hirao F; Yamamura Y
    Cancer Res; 1981 Feb; 41(2):660-6. PubMed ID: 6969630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
    Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
    Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection by S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation- and cyclophosphamide-induced attenuation in antitumor resistance.
    Milas L; McBride WH; Hunter N; Ito H
    Cancer Res; 1984 Jun; 44(6):2382-6. PubMed ID: 6327014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation and suppression of graft-vs-host reactions by cyclophosphamide.
    Wander RH; Hilgard HR
    J Immunol; 1981 Mar; 126(3):901-4. PubMed ID: 7462635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma.
    Morikawa K; Hosokawa M; Hamada J; Sugawara M; Kobayashi H
    Cancer Res; 1985 Apr; 45(4):1502-6. PubMed ID: 2579730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble suppressor factor from the spleens of tumor-bearing mice.
    Subramanian C; Yu S; McKhann CF
    Cancer Res; 1978 Jul; 38(7):1996-2002. PubMed ID: 657137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of immunosuppressor cells in rats immunized with solubilized tumor-associated antigens prepared from a methylcholanthrene-induced fibrosarcoma.
    Minami A; Kasai M; Mizushima Y; Takeichi N; Hosokawa M; Kobayashi H
    Cancer Res; 1980 Jul; 40(7):2129-34. PubMed ID: 6446378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.
    Tsung K; Dolan JP; Tsung YL; Norton JA
    Cancer Res; 2002 Sep; 62(17):5069-75. PubMed ID: 12208763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the mechanism of allograft rejection and cell-mediated immunity. II. Divergent effect of CY pretreatment on the generation of cytotoxic activity in the draining lymph nodes and spleen.
    Nanishi F; Taniguchi K; Kubo C; Onoyama K; Omae T; Nomoto K
    J Clin Lab Immunol; 1983 Sep; 12(1):23-30. PubMed ID: 6631941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
    Mokyr MB; Dray S
    Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro.
    Tomazic VJ; Farha M; Loftus A; Elias EG
    J Immunol; 1988 Jun; 140(11):4056-61. PubMed ID: 3372997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytostatic effect of spleen cells of tumor-bearing mice on syngenetic tumor cells.
    Lespinats G; Poupon MF
    Cancer Res; 1977 Jun; 37(6):1727-32. PubMed ID: 870185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.